Radius Health company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

radiuspharm.com

Founded Year

2003

Stage

Acq - Pending | Acquired

Total Raised

$224.5M

Valuation

$0000 

About Radius Health

Radius Health is a biopharmaceutical company focused on developing new therapeutics to treat osteoporosis and other women's health conditions. It is committed to the development of therapeutics for the osteoporosis market. The company's lead product candidate, BA058-SC, is in effect to reduce the risk of complications associated with osteoporosis, such as fractures and has a transdermal patch, BA058-TD, being developed as a short wear-time delivery vehicle intended to improve patient compliance with convenience and ease of use, as well as a product in development to treat symptoms associated with menopause. The company was founded in 2003 and is based in Boston, Massachusetts.

Radius Health Headquarter Location

22 Boston Wharf Rd 7th Floor

Boston, Massachusetts, 02210,

United States

617-551-4000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Radius Health

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Radius Health is included in 2 Expert Collections, including Women's Health & Wellness.

W

Women's Health & Wellness

1,471 items

Startups focused on providing products and services catering to women's health and wellbeing.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Radius Health Patents

Radius Health has filed 33 patents.

The 3 most popular patent topics include:

  • G protein coupled receptors
  • Rare diseases
  • Bone fractures
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/7/2021

2/22/2022

G protein coupled receptors, Immunology, Immune system, Clusters of differentiation, Antibodies

Grant

Application Date

7/7/2021

Grant Date

2/22/2022

Title

Related Topics

G protein coupled receptors, Immunology, Immune system, Clusters of differentiation, Antibodies

Status

Grant

Latest Radius Health News

Gurnet Point Capital and Patient Square Capital Complete Their Acquisition of Radius Health, Inc.

Aug 15, 2022

Boston, Massachusetts, UNITED STATES CAMBRIDGE, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Gurnet Point Capital (“Gurnet Point”) and Patient Square Capital (“Patient Square”) announced today the completion of their acquisition of Radius Health, Inc. (Nasdaq: RDUS) (“Radius”). Radius is a global, commercial-stage biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health and neuro-orphan diseases. Radius’ lead product, TYMLOS® (abaloparatide) was launched in the U.S. in 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The consideration paid to shareholders in the transaction was $10.00 per share in cash, plus one non-transferable contingent value right (“CVR”) per share, which represents the contractual right to receive $1.00 per share in cash, payable upon TYMLOS net sales reaching $300 million (inclusive of U.S. sales and Japan royalties or supply payments based on supply of TYMLOS for sale in Japan) during any consecutive 12-month period prior to December 31, 2025. As of the tender offer expiration, the shares validly tendered and not withdrawn represented over 50% of the outstanding shares of common stock of Radius. Pursuant to the terms of the merger agreement, the purchaser entity for Gurnet Point and Patient Square merged with and into Radius, and as a result, Radius has become a wholly-owned indirect subsidiary of Gurnet Point and Patient Square. Radius will be delisted from the NASDAQ Global Market. About Gurnet Point Capital Gurnet Point Capital is a leading healthcare fund that invests in de-risked life sciences companies. Gurnet Point primarily focuses on businesses that have high growth potential in the late product development and commercialization stages of their evolution. These companies become partners not just because of their capacity to generate economic value, but also because of their potential to deliver social impact. Gurnet Point’s team of highly experienced industry executives work closely with its portfolio companies, with an active approach driving operational transformation and outsized returns. www.gurnetpointcapital.com About Patient Square Capital Patient Square Capital ( www.patientsquarecapital.com ) is a dedicated health care investment firm that partners with best-in-class management teams whose products, services and technologies improve health. Patient Square utilizes deep industry expertise, a broad network of relationships and a true partnership approach to make investments in companies grow and thrive. Patient Square invests in businesses that strive to improve patient lives, strengthen communities and create a healthier world. Patient Square’s team of industry-leading executives is differentiated by the depth of focus in health care, the breadth of health care investing experience, and the network it can activate to drive differentiated outcomes. About Radius Radius is a global biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health, neuro- orphan diseases, and oncology. Radius’ lead product, TYMLOS® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group; and the investigational drug RAD011, a synthetic cannabidiol oral solution with potential utilization in multiple neuro-endocrine, neurodevelopmental, or neuropsychiatric disease areas, initially targeting Prader-Willi syndrome, Angelman syndrome, and infantile spasms. Media Contact:

Radius Health Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Radius Health Rank

  • When was Radius Health founded?

    Radius Health was founded in 2003.

  • Where is Radius Health's headquarters?

    Radius Health's headquarters is located at 22 Boston Wharf Rd, Boston.

  • What is Radius Health's latest funding round?

    Radius Health's latest funding round is Acq - Pending.

  • How much did Radius Health raise?

    Radius Health raised a total of $224.5M.

  • Who are the investors of Radius Health?

    Investors of Radius Health include Gurnet Point Capital, Patient Square Capital, MPM Capital, BB Biotech Ventures, Bain Capital Public Equity and 17 more.

  • Who are Radius Health's competitors?

    Competitors of Radius Health include Aquinox Pharmaceuticals, Aegerion Pharmaceuticals, Athenex, Neuraltus Pharmaceuticals, Hyperion Therapeutics and 12 more.

You May Also Like

A
Alvine Pharmaceuticals

Alvine Pharmaceuticals is a clinical-stage, specialty biopharmaceutical company focused on the development of biologics targeting autoimmune and inflammatory diseases, including celiac disease. Alvine is focusing clinical development efforts on ALV003, an investigational drug in phase 2 trials that could potentially be the first approved therapeutic treatment for patients with celiac disease. ALV003 is an orally administered mixture of two recombinant gluten-specific proteases, a cysteine protease (EP-B2) and a prolyl endopeptidase (PEP). ALV003 targets gluten and degrades it into small fragments, which, in vitro, diminishes its immunogenicity. ALV003 is being developed as a potential treatment for celiac disease patients in conjunction with a gluten-free diet and is currently in phase 2 clinical development.

M
MacuSight

MacuSight is a privately-held pharmaceutical company focused on developing innovative therapeutics for the treatment of severe ocular diseases and conditions. The company is dedicated to preserving patients' vision by identifying known, highly-potent and broad-acting small molecule drug compounds that may possess efficacy in treating and/or preventing diseases or conditions of the eye. As part of its unique product development philosophy, MacuSight also concentrates on the optimal delivery of these compounds into the eye. By combining its compounds with innovative delivery approaches, the company strives to optimize the efficacy, safety, convenience and cost-effectiveness of its product candidates.

N
Neuraltus Pharmaceuticals

Neuraltus Pharmaceuticals is a privately-held biopharmaceutical company dedicated to developing and commercializing innovative therapeutics that address critical unmet needs for patients and physicians in the treatment of neurodegenerative diseases. The Company is collaborating with global ALS specialists and seeking input from patient advocacy organizations to help inform the clinical development path and better understand the needs of people affected by the disease.

R
Renovo

Renovo provides drug discovery and development for scar prevention and reduction.

V
Verus Pharmaceuticals

Verus Pharmaceuticals is developing products treating asthma

A
Altheos

Altheos, Inc. is an early-stage biopharmaceutical company focused on the identification and development of promising well-differentiated novel small molecule drugs for unmet medical needs. Altheos, Inc. was co-founded in 2009 by two experienced pharmaceutical drug development executives and entrepreneurs, Henry H. Hsu, M.D. and M. (Ken) Kengatharan, Ph.D. The company is headquartered in South San Francisco, California.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.